Novel immunotherapy leads to complete regression of chemotherapy-resistant liver cancer in 3-year-old
A new report in the New England Journal of Medicine by researchers at Baylor College of Medicine, Texas Children's Hospital and Seattle Children's describes a complete regression of hepatoblastoma, the most common pediatric liver cancer, in a 3-year-old treated with a novel immunotherapy.
We haven't written up this one. Medical Xpress has the full story — the link below goes straight to it.
